BioSpace News Archive

In an effort to change the course of this pandemic, advancing lead COVID-19 therapeutics requires matched supply chain efforts and expertise to meet the continued and urgent patient needs.

GenSight Biologics announced that it has submitted the Marketing Authorisation Application for its lead product LUMEVOQ® to the European Medicines Agency, seeking approval for the treatment of patients with vision loss due to Leber Hereditary Optic Neuropathy caused by mutation in the ND4 mitochondrial gene.

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company with its lead compound RLF-100 in advanced clinical development to treat severe COVID-19 patients, announced its results for the half year ended June 30, 2020.

Easyfairs Northeral, the organizer of MAGHREB PHARMA Expo has announced new dates for its annual international tradeshow for the pharmaceutical industry in North Africa.

Presentations across multiple tumour types, including six focused on hard-to-treat cancers in women, demonstrate progress in accelerating potentially transformational medicines

Juvenescence Limited, a life sciences company focused on modifying aging and increasing human healthspan, announced a partnership with Evgen Pharma plc to license its sulforaphane stabilization technology for use in several non-pharmaceutical applications led by its JuvLife division.

In the search for a preventative treatment of skin cancers, including melanoma, it is imperative to understand and treat DNA damage caused by ultraviolet radiation.

Novaremed AG, a clinical-stage Swiss biopharmaceutical company, announced that it has raised CHF2.5 million from its existing shareholders in an oversubscribed new financing round.

Skull fractures are the most common type of head and facial fracture among skateboarding injuries in the emergency department, and a new study warns of the effects of these fractures, particularly in children.

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, announced it has signed an agreement with Applied StemCell, Inc., a leading provider of stem cell, animal model, antibody discovery services and reagents.